Versant Capital Management Inc Sells 1,241 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Versant Capital Management Inc reduced its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 32.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,642 shares of the company’s stock after selling 1,241 shares during the quarter. Versant Capital Management Inc’s holdings in Elanco Animal Health were worth $32,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. boosted its position in Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after acquiring an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC bought a new stake in shares of Elanco Animal Health during the 3rd quarter valued at about $29,000. AM Squared Ltd acquired a new stake in Elanco Animal Health during the third quarter worth approximately $34,000. Wilmington Savings Fund Society FSB acquired a new stake in Elanco Animal Health during the third quarter worth approximately $35,000. Finally, Quarry LP bought a new stake in Elanco Animal Health in the second quarter worth approximately $40,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Leerink Partners started coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price on the stock. Stifel Nicolaus decreased their price target on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday. Barclays upped their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Finally, UBS Group initiated coverage on Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Elanco Animal Health has a consensus rating of “Hold” and an average target price of $16.43.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $11.81 on Wednesday. Elanco Animal Health Incorporated has a 52 week low of $11.40 and a 52 week high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock has a 50 day moving average price of $12.73 and a two-hundred day moving average price of $13.57. The firm has a market capitalization of $5.84 billion, a P/E ratio of 29.53, a P/E/G ratio of 2.03 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.01. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health’s revenue was down 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.18 earnings per share. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.